<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Travel advice for immunocompromised hosts</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Travel advice for immunocompromised hosts</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Travel advice for immunocompromised hosts</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Camille N Kotton, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Karin Leder, MBBS, FRACP, PhD, MPH, DTMH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elinor L Baron, MD, DTMH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 06, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Immunocompromised hosts represent a broad spectrum of immune suppression. A first step in providing travel advice is determining the extent of infection risk, which must be considered on an individual basis. (See <a class="local">'Assessing immune status'</a> below.)</p><p>Immunocompromised hosts traveling overseas may be at higher risk for travel-related infections than immunocompetent individuals. In general, the vaccine response rate in these patients is diminished, and they may be more likely to have adverse effects from vaccines containing live attenuated virus. Guidelines on travel medicine and solid organ transplant recipients have been updated [<a href="#rid1">1</a>]. Latin America-specific travel recommendations for solid organ transplant recipients have also been published [<a href="#rid2">2</a>].</p><p>The coronavirus disease 2019 (COVID-19) pandemic has had a major influence on the ability of immunocompromised patients to travel safely. Although they may have received numerous vaccines and/or monoclonal antibodies, diminished efficacy of these interventions result in diminished protection. Where possible, providers may wish to plan ahead for such events; drug interactions, regulatory issues, and limited availability of therapeutics are major hurdles [<a href="#rid3">3</a>].</p><p>Issues related to travel-related vaccines in adult immunocompromised hosts without human immunodeficiency virus (HIV) will be reviewed here. Issues related to travel-related vaccines in immunocompetent hosts are discussed separately, as are issues related to routine immunizations for these groups. (See  <a class="medical medical_review" href="/z/d/html/3890.html" rel="external">"Immunizations for travel"</a> and  <a class="medical medical_review" href="/z/d/html/3882.html" rel="external">"Immunizations in hematopoietic cell transplant candidates and recipients"</a> and  <a class="medical medical_review" href="/z/d/html/3899.html" rel="external">"Immunizations in adults with cancer"</a> and  <a class="medical medical_review" href="/z/d/html/3706.html" rel="external">"Immunizations in persons with HIV"</a> and  <a class="medical medical_review" href="/z/d/html/3892.html" rel="external">"Immunizations in solid organ transplant candidates and recipients"</a>.)</p><p class="headingAnchor" id="H4046391077"><span class="h1">ASSESSING IMMUNE STATUS</span><span class="headingEndMark"> — </span>Moderate and severe immunocompromising conditions and treatments include but are not limited to:</p><p class="bulletIndent1"><span class="glyph">●</span>Active treatment for solid tumor and hematologic malignancies.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hematologic malignancies associated with poor responses to COVID-19 vaccine, regardless of current treatment status (eg, chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, and acute leukemia).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Receipt of solid organ transplant or an islet transplant and taking immunosuppressive therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Receipt of chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic cell transplant (HCT; within two years of transplantation or taking immunosuppressive therapy). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Moderate or severe primary immunodeficiency (eg, common variable immunodeficiency disease, severe combined immunodeficiency, DiGeorge syndrome, Wiskott-Aldrich syndrome).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Advanced HIV infection (people with HIV and CD4 cell count &lt;200/mm<sup>3</sup>, history of an AIDS-defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV) or untreated HIV infection. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Active treatment with high-dose corticosteroids (ie, 20 mg or more of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> or equivalent per day when administered for two or more weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, tumor necrosis factor (TNF) blockers, and other biologic agents that are immunosuppressive or immunomodulatory (eg, B-cell-depleting agents).</p><p></p><p>Considerations in assessing the general level of immune competence in a patient include disease severity, duration, clinical stability, complications, comorbidities, and any potentially immune-suppressing treatment. Factors that should not be used to determine the level of immune competence include age or place of residence alone (eg, residence in a long-term care setting), independent of a patient’s medical condition. </p><p>For additional information about the degree of immune suppression associated with different medical conditions and treatments, providers can consult the Advisory Committee on Immunization Practices' (ACIP) general best practices for vaccination of people with altered immunocompetence, the United States Centers for Disease Control and Prevention (CDC) Yellow Book, and guidance from the Infectious Diseases Society of America (IDSA) [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H3635047027"><span class="h1">PURPOSE OF PRETRAVEL VISIT</span><span class="headingEndMark"> — </span>Immunocompromised hosts planning to travel overseas should be evaluated by a travel medicine specialist familiar with the patient's immunocompromised state and medications [<a href="#rid5">5-10</a>]. Travel health specialists for complex patients should confer with the traveler's other providers as needed to develop an appropriate plan. Given the broad spectrum of immune compromise, an assessment of risk is an important part of the pretravel visit  (<a class="graphic graphic_table graphicRef56079" href="/z/d/graphic/56079.html" rel="external">table 1</a>) [<a href="#rid7">7,10</a>]. </p><p>Immunocompromised hosts may wish to defer travel until they are less immunocompromised (eg, until one year after solid organ transplant or two years after hematopoietic stem cell transplant). Weighing the risk and benefits of travel for these more vulnerable patients may be an important part of the visit. In addition, other essential parts of the visit may include discussing food and water precautions, hand hygiene, measures to undertake if illness develops, specific antimicrobial prophylaxis (ie, for malaria), self-treatment of diarrhea with antibiotics, and updating both routine and travel-related vaccines (or use of immunoglobulins if necessary). (See  <a class="medical medical_review" href="/z/d/html/3898.html" rel="external">"Travel advice"</a>.)</p><p>Complexity of medication timing can be challenging for patients on a strict regimen and who are changing time zones, such as those who are on organ transplant-related medication or living with HIV. These patients may benefit from an explicit discussion regarding best approach to medication timing, to avoid toxicity or therapeutic gaps [<a href="#rid11">11</a>].</p><p class="headingAnchor" id="H4076983885"><span class="h1">TIMING OF VACCINATION</span><span class="headingEndMark"> — </span>Vaccination should be initiated several months prior to travel when possible to allow time for serologic testing and additional boosters if needed. Ideally, immunocompromised hosts should be vaccinated during periods of minimal or no exogenous immunosuppression to optimize the immunologic response (eg, before solid organ or hematopoietic stem cell transplant, before biologic immunomodulators are given, etc) [<a href="#rid12">12,13</a>]. Vaccination is least effective in the initial months after solid organ or hematopoietic stem cell transplant since this is usually the period of highest immunosuppression [<a href="#rid14">14,15</a>]. (See  <a class="medical medical_review" href="/z/d/html/3892.html" rel="external">"Immunizations in solid organ transplant candidates and recipients"</a>.)</p><p>Timing of vaccination for patients on chronic immunosuppression is poorly studied; the clinician must weigh the benefits of reducing or suspending the immunosuppressive regimen with the risk of disease flare, organ rejection, and the subsequent potential need for more potent immunosuppression. Worsening of disease while traveling could become a medical emergency, requiring careful consideration and contingency planning.</p><p>In general, a fourfold increase in antibody titer (or titer above a designated threshold) is considered evidence of seroconversion. Immunocompromised hosts are less likely to have a significant immunologic response, although they may still benefit from partial protection.</p><p>Immune responses to vaccination may wane more rapidly in immunocompromised individuals than other hosts [<a href="#rid15">15</a>]. Booster doses of vaccine may be administered in the setting of low or undetectable antibody titers, although the efficacy for this has not been demonstrated.</p><p>The response to vaccination can be variable. Among 292 allogeneic transplant recipients, 89 percent of those who failed to mount a response to the recombinant hepatitis B vaccine mounted at least a threefold rise in polio titers following three doses of inactivated poliovirus [<a href="#rid16">16</a>]. Studies on the efficacy or seroconversion following most travel vaccines in immunocompromised hosts have not been performed.</p><p class="headingAnchor" id="H1730188903"><span class="h1">VACCINES</span></p><p class="headingAnchor" id="H469107340"><span class="h2">Travel vaccines</span></p><p class="headingAnchor" id="H3908638281"><span class="h3">Hepatitis A</span><span class="headingEndMark"> — </span>Hepatitis A can be a devastating illness in immunocompromised hosts [<a href="#rid17">17</a>]. These patients have attenuated immunologic response and shortened durability of response to <a class="drug drug_general" data-topicid="8519" href="/z/d/drug information/8519.html" rel="external">hepatitis A vaccine</a> [<a href="#rid18">18,19</a>]. Seroconversion rates to vaccination may depend on immunosuppressive medications, medical comorbidities, and type of vaccine used [<a href="#rid20">20-22</a>]. In one series including 39 liver and 39 renal transplant recipients who received two doses of hepatitis A vaccine six months apart, response rates among liver transplant recipients were 41 and 97 percent, and response rates among renal transplant recipients were 24 and 72 percent [<a href="#rid22">22</a>]. Similar results were found in 53 patients with rheumatoid arthritis on <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> and/or tumor necrosis factor (TNF)-alpha treatment; at one and six months after the first dose, 10 and 33 percent had attained seroprotection, and, at one and six months after the second dose, 83 and 72 percent were seroprotected [<a href="#rid23">23</a>].</p><p>Thus, vaccination with two doses of <a class="drug drug_general" data-topicid="8519" href="/z/d/drug information/8519.html" rel="external">hepatitis A vaccine</a> 6 to 12 months apart may be most protective for immunocompromised hosts who are on a modest immunosuppressive regimen, if there is enough time before travel [<a href="#rid24">24</a>]. Titers may be checked to document seroconversion, although there is often insufficient time prior to travel. For patients without sufficient time for two separate doses of vaccine prior to travel, administration of a double dose of hepatitis A vaccine (followed by booster at six months) has been proposed as an alternative approach. Preliminary data among patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors or <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> appear promising; further study is needed [<a href="#rid25">25</a>]. </p><p>Intramuscular gamma globulin (consisting of pooled immunoglobulins) is 85 to 90 percent protective against hepatitis A infection; this effect lasts for up to several months, depending on the dose given. Immunocompromised hosts with hypogammaglobulinemia who receive routine intravenous immunoglobulin (<a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a>) do not need additional antibody protection for hepatitis A, measles, or varicella.</p><p>Moderately to significantly immunosuppressed hosts who do not have sufficient time for immunization prior to travel or who are unlikely to respond to immunization can be given intramuscular immunoglobulin prior to travel [<a href="#rid10">10,26</a>]. For less immunocompromised hosts, vaccination alone may be adequate. (See  <a class="medical medical_review" href="/z/d/html/3900.html" rel="external">"Hepatitis A virus infection: Treatment and prevention"</a>.)</p><p class="headingAnchor" id="H1809516846"><span class="h3">Salmonella enterica serovar Typhi</span><span class="headingEndMark"> — </span>Approximately 350 cases of typhoid fever are reported in the United States each year, although there are many more unreported cases, estimated to be 5700 infections of <em>Salmonella enterica</em> serovar Typhi; most are related to international travel [<a href="#rid27">27,28</a>] . Immunocompromised individuals may have severe complications during infection with <em>Salmonella enterica</em> serovar Typhi<em> </em>and should be immunized against typhoid prior to travel to endemic areas.</p><p>There are two vaccines available: Typhim Vi (Aventis Pasteur SA), an injectable polysaccharide vaccine, and Vivotif (Ty21a, Berna) an oral live attenuated vaccine. Both are generally well tolerated [<a href="#rid29">29</a>]. The inactive parenteral vaccine is recommended for immunocompromised individuals, as the oral <a class="drug drug_general" data-topicid="10030" href="/z/d/drug information/10030.html" rel="external">typhoid vaccine</a> is a live bacteria vaccine that could theoretically cause disseminated disease [<a href="#rid10">10</a>]. The immune response in immunocompromised hosts to either vaccine is usually poor, and efficacy in immunocompromised hosts is unknown. (See  <a class="medical medical_review" href="/z/d/html/2712.html" rel="external">"Enteric (typhoid and paratyphoid) fever: Treatment and prevention"</a>.) </p><p class="headingAnchor" id="H3115473395"><span class="h3">Polio</span><span class="headingEndMark"> — </span>Poliomyelitis due to wild-type poliovirus has been eradicated from the Western hemisphere; wild-type virus exists in sub-Saharan Africa and Asia. Outbreaks of vaccine-associated poliomyelitis occasionally occur due to reversion of live attenuated poliovirus from the oral polio vaccine. Such outbreaks have occurred in Hispaniola (Haiti and the Dominican Republic), the Philippines, Madagascar, and Cape Verde.</p><p>Two forms of polio vaccine are available: the orally administered, live attenuated virus (OPV or Sabin) and the injected inactivated <a class="drug drug_general" data-topicid="9787" href="/z/d/drug information/9787.html" rel="external">poliovirus vaccine</a> (IPV or Salk). Immunocompromised hosts and household contacts of immunocompromised individuals should not receive OPV, since attenuated vaccine strain polioviruses may spread through fecal-oral contact. OPV is no longer distributed in many countries, including the United States and Canada.</p><p>In general, travelers should have received a primary series of polio vaccine during childhood and at least one booster as an adult. Some authorities recommend booster immunization if more than 10 years have elapsed since administration of the last polio vaccine, especially for individuals traveling to areas of the world with circulating wild-type polio viruses or a polio outbreak. Booster vaccination with the injectable nonlive IPV would seem prudent for immunocompromised hosts. In certain regions with active transmission of wild poliovirus, travelers should travel with an official certificate of vaccination that records their polio vaccination status within 4 to 52 weeks (such as the International Certificate of Vaccination or Prophylaxis).</p><p>Poliovirus immunity is relatively well maintained after revaccination among patients with allogeneic stem cell transplant (SCT). In a study of 134 patients who received three doses of inactivated polio vaccine beginning 12 months after hematopoietic stem cell transplantation (HSCT), the estimated probabilities of remaining immune to poliovirus at 5 and 10 years after vaccination were 94 and 94 percent for subtype 1, 98 and 94 percent for subtype 2, and 93 and 90 percent for subtype 3, respectively [<a href="#rid30">30</a>]. Patients with chronic graft-versus-host disease (GVHD) lost immunity more rapidly than those without GVHD. Response to vaccination after solid organ transplantation (SOT) has not been well studied. (See  <a class="medical medical_review" href="/z/d/html/2695.html" rel="external">"Poliovirus vaccination"</a>.)</p><p class="headingAnchor" id="H1662583229"><span class="h3">Meningococcus</span><span class="headingEndMark"> — </span>Meningococcal disease has a high case-fatality rate (5 to 15 percent). The meningococcal vaccine is indicated for individuals traveling to areas of the world with known outbreaks of invasive meningococcal disease, to the meningitis belt of sub-Saharan Africa (especially during the dry winter months of December through June), and to Saudi Arabia for the Muslim pilgrimages of Hajj or Umrah, where proof of vaccination is required.</p><p>Immunocompromised hosts are at increased risk for morbidity and mortality from meningococcal disease; vaccination is appropriate for those with exposure to regions with active disease. In the United States, several <a class="drug drug_general" data-topicid="10140" href="/z/d/drug information/10140.html" rel="external">quadrivalent meningococcal conjugate vaccine</a> (MenACWY) formulations are available (Menactra, Menveo, MenQuadfi). Two doses of vaccine are recommended for immunocompromised hosts [<a href="#rid31">31</a>]. Two vaccines, MenB-FHbp (Trumenba) and MenB-4C (Bexsero), have been approved by the US Food and Drug Administration (FDA) to prevent invasive meningococcal disease caused by <em>Neisseria meningitidis</em> serogroup B. Similar vaccines are available in other regions. Individuals who were vaccinated previously and are at prolonged increased risk (ie, asplenia, other immunocompromised states) require booster doses  (<a class="graphic graphic_table graphicRef130149" href="/z/d/graphic/130149.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef130150" href="/z/d/graphic/130150.html" rel="external">table 3</a>) [<a href="#rid31">31</a>].</p><p>Among 44 adult HSCT recipients randomized to receive polysaccharide meningococcal vaccine either 8 or 20 months after transplant, the majority had significant immune responses to serogroups A and C; these responses were lower in the former group (8 months) than the latter group (20 months) [<a href="#rid32">32</a>]. The immune responses declined sharply over the first 6 to 12 months after vaccination, suggesting revaccination should be performed for those at risk of exposure to meningococcal infection. Chronic GVHD had no influence on the vaccination response. In a trial of 67 autologous or allogeneic stem cell transplant recipients who were vaccinated with a single dose of conjugate quadrivalent meningococcal vaccine, the majority developed protective titers, although the authors suggested that they may benefit from receipt of a second dose [<a href="#rid33">33</a>]. </p><p>Among 38 pediatric HSCT recipients, 100 percent response to polysaccharide meningococcal serogroup C was observed two to four weeks after vaccination [<a href="#rid34">34</a>]. Among 25 pediatric oncology patients, response to meningococcal C conjugate vaccine was variable; those with lower serologic response rates were more likely to be receiving chemotherapy or have lower B cell counts [<a href="#rid35">35</a>].</p><p>A study of 19 adolescent kidney transplant patients who underwent vaccination with meningococcal conjugate vaccine (<a class="drug drug_general" data-topicid="10140" href="/z/d/drug information/10140.html" rel="external">MenACWY-D</a>) showed that at four weeks postvaccination, 41 percent had seroconverted to all four serogroups, with seroconversion rates of 88, 53, 71, and 94 percent for serogroups A, C, W, and Y [<a href="#rid36">36</a>], suggesting a need for alternative dosing schedules. There are no published data regarding the response of adult solid organ transplant recipients to immunization with the polysaccharide or protein conjugate meningococcal vaccine. (See  <a class="medical medical_review" href="/z/d/html/3892.html" rel="external">"Immunizations in solid organ transplant candidates and recipients", section on 'Meningococcus'</a>.)</p><p class="headingAnchor" id="H144163011"><span class="h3">Yellow fever</span><span class="headingEndMark"> — </span>Yellow fever is a mosquito-borne viral hemorrhagic fever that occurs in tropical regions of South America and sub-Saharan Africa. Case fatality may surpass 20 percent; no specific treatment exists.</p><p>In general, immunocompromised travelers should avoid regions where yellow fever is endemic [<a href="#rid4">4</a>]. The <a class="drug drug_general" data-topicid="10051" href="/z/d/drug information/10051.html" rel="external">yellow fever vaccine</a> contains a live attenuated viral strain and, as a rule, this vaccine should not be administered to immunocompromised hosts [<a href="#rid10">10,37-41</a>]. The CDC guidelines suggest that yellow fever vaccine can be given to those with asplenia, renal failure, chronic liver disease, and diabetes but not to those with more severe immunosuppression [<a href="#rid10">10</a>], including those on high-dose systemic corticosteroids, TNF-alpha inhibitors (such as <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">etanercept</a>), interleukin-1– and interleukin-6–blocking agents (such as <a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">anakinra</a> and <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">tocilizumab</a>), other immunosuppressive monoclonal antibodies targeting immune cells (such as <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> or <a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">alemtuzumab</a>), alkylating drugs, and antimetabolites, as they are presumed to be at increased risk for yellow fever vaccine-associated serious adverse events [<a href="#rid10">10</a>]. Even in endemic regions, patients and clinicians may not be aware of this contraindication to vaccination [<a href="#rid42">42</a>].</p><p>After discontinuation of high-dose systemic corticosteroid therapy, clinicians should wait at least one month before administering a live-virus vaccine [<a href="#rid10">10</a>]. Some experts recommend waiting one month after discontinuing <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">etanercept</a> and three months after discontinuing the other TNF blockers before administering a live-virus vaccine [<a href="#rid43">43</a>]. Prolonged immunosuppression can occur with lymphocyte-depleting agents such as <a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">alemtuzumab</a> and <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>; the optimal time for vaccination before or after such agents is unknown. Reinitiation of immunosuppression after live-virus vaccination has not been studied; some experts would recommend waiting at least one month depending on the mechanism of immunosuppression [<a href="#rid10">10</a>].</p><p>Thymic dysfunction has been found to be an independent risk factor for the development of <a class="drug drug_general" data-topicid="10051" href="/z/d/drug information/10051.html" rel="external">yellow fever vaccine</a>–associated viscerotropic disease, and health care providers should ask about a history of thymus disorder, including myasthenia gravis, thymoma, or prior thymectomy [<a href="#rid44">44</a>]. Fatal myeloencephalitis following yellow fever vaccination have been reported in immunosuppressed individuals [<a href="#rid45">45,46</a>].</p><p>Immunocompromised travelers who cannot avoid travel to endemic regions should be counseled to avoid traveling during peak seasons for yellow fever transmission and minimize exposure to mosquitoes (ie, during the elevated risk period in rural West Africa during the end of the rainy season and the beginning of the dry season [usually July to October] and during the rainy season in South America [January to May, with a peak incidence in February and March]) [<a href="#rid10">10</a>].</p><p>Immunocompromised patients who previously underwent yellow fever vaccination appear to have durable neutralizing antibody responses, similar to normal hosts [<a href="#rid47">47,48</a>]. Given the World Health Organization (WHO) recommendation for a single dose of vaccine, it may be acceptable to presume immunity to yellow fever after a single lifetime dose, especially weighing the risks of revaccination in immunocompromised patients. It is not known whether prior vaccine may alter the risk of such complications. </p><p>Some mildly immunosuppressed individuals have tolerated the vaccine (including individuals with early HIV infection or a distant history of hematologic malignancy without recent immunosuppressive therapy) [<a href="#rid49">49-52</a>]. The CDC recommends that, for those with HIV and CD4 count &lt;200/mm<sup>3</sup>, <a class="drug drug_general" data-topicid="10051" href="/z/d/drug information/10051.html" rel="external">yellow fever vaccine</a> is contraindicated, a medical waiver should be provided, and counseling on protective measures against mosquito bites should be emphasized [<a href="#rid10">10</a>]. For those with 200 to 500 CD4/mm<sup>3</sup>, the CDC recommends that vaccination may be considered with a plan for close monitoring, unless such vaccination is only to fulfill international travel requirements, in which case the individual should be excused from immunization and issued a yellow fever vaccine medical waiver. The CDC recommends that an asymptomatic HIV-infected person with no evidence of immune suppression and CD4 ≥500/mm<sup>3</sup> can be administered yellow fever vaccine when indicated.</p><p>In a retrospective study of 70 patients with rheumatologic conditions who received the <a class="drug drug_general" data-topicid="10051" href="/z/d/drug information/10051.html" rel="external">yellow fever vaccine</a> in Brazil, 23 percent reported some minor adverse effect; this rate is comparable to adverse reactions among immunocompetent individuals [<a href="#rid53">53</a>]. </p><p>Final decision regarding vaccination should be made with careful consideration of risks and benefits. For patients who cannot avoid travel to endemic regions but do not receive vaccination, a physician's letter stating contraindications to vaccination with the stamp of an approved yellow fever immunization center is acceptable to most governments . Some countries may deny entry without immunization; patients should be aware that deportation might be preferable to receipt of <a class="drug drug_general" data-topicid="10051" href="/z/d/drug information/10051.html" rel="external">yellow fever vaccine</a> at the destination. (See  <a class="medical medical_review" href="/z/d/html/3032.html" rel="external">"Yellow fever: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H4037755113"><span class="h3">Rabies</span><span class="headingEndMark"> — </span>Candidates for pre-exposure immunization against rabies include travelers expecting intense animal exposure, travelers planning to be far from medical care, and long-term travelers.</p><p>Immunocompromised hosts may not mount adequate antibody responses to the <a class="drug drug_general" data-topicid="9850" href="/z/d/drug information/9850.html" rel="external">rabies vaccine</a> (titers &gt;0.5 international units [IU]/mL); efficacy data for rabies data are minimal in SOT and HSCT recipients. It may be reasonable to administer rabies vaccination to individuals with significant exposure risks factors, although human rabies immunoglobulin should also be administered after all risk exposures [<a href="#rid54">54</a>]. (See  <a class="medical medical_review" href="/z/d/html/8328.html" rel="external">"Indications for post-exposure rabies prophylaxis"</a>.)</p><p class="headingAnchor" id="H3064579633"><span class="h3">Japanese encephalitis</span><span class="headingEndMark"> — </span>Immunization against Japanese encephalitis (JE) with the inactivated vaccine (Jepect/Ixiaro) rather than the live Imojev vaccine (which would be contraindicated) is appropriate for individuals traveling to rural areas of Asia where JE is endemic, especially during periods of increased transmission [<a href="#rid10">10,55</a>]. (See  <a class="medical medical_review" href="/z/d/html/3034.html" rel="external">"Japanese encephalitis"</a>.)</p><p class="headingAnchor" id="H1915046104"><span class="h3">Bacille Calmette-Guérin</span><span class="headingEndMark"> — </span>Bacille Calmette-Guérin (BCG) is a live attenuated strain of <em>Mycobacterium bovis</em> for the prevention of tuberculosis. BCG should not be administered to immunocompromised host as it can cause disseminated infection.</p><p>Immunocompromised hosts may wish to wear masks when in health care settings in areas endemic for tuberculosis. Pre- and post-travel tuberculosis skin tests with the purified protein derivative may be performed but are likely to be negative in the immunocompromised population. Interferon-gamma release assays for tuberculosis are generally more sensitive in this population. (See  <a class="medical medical_review" href="/z/d/html/15352.html" rel="external">"Use of interferon-gamma release assays for diagnosis of tuberculosis infection (tuberculosis screening) in adults"</a>.) </p><p class="headingAnchor" id="H3"><span class="h2">Routine vaccines</span><span class="headingEndMark"> — </span>Travel advice encounters provide the opportunity to review routine immunizations that may have been overlooked. Information on routine vaccinations in immunocompromised hosts is summarized in the tables  (<a class="graphic graphic_table graphicRef66152" href="/z/d/graphic/66152.html" rel="external">table 4</a> and <a class="graphic graphic_table graphicRef91882" href="/z/d/graphic/91882.html" rel="external">table 5</a> and <a class="graphic graphic_figure graphicRef62130" href="/z/d/graphic/62130.html" rel="external">figure 1</a> and <a class="graphic graphic_figure graphicRef82634" href="/z/d/graphic/82634.html" rel="external">figure 2</a>) and discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/3892.html" rel="external">"Immunizations in solid organ transplant candidates and recipients"</a> and  <a class="medical medical_review" href="/z/d/html/3882.html" rel="external">"Immunizations in hematopoietic cell transplant candidates and recipients"</a> and  <a class="medical medical_review" href="/z/d/html/3899.html" rel="external">"Immunizations in adults with cancer"</a>.)</p><p>The pretravel clinic visit is a good opportunity to update routine vaccines. It is only necessary to administer a routine vaccine if it has not been previously received, appropriately updated, or if there is reason to think that immunity has waned such revaccinating is necessary. </p><p class="headingAnchor" id="H4"><span class="h3">Tetanus</span><span class="headingEndMark"> — </span>Tetanus boosters should be up to date before traveling. Tetanus is rare in the industrialized world where vaccination rates are quite good; the prevalence is much higher in resource-limited settings, although it is rare among travelers. Vaccination is appropriate for travelers to regions where tetanus is endemic who were vaccinated more than 10 years previously. (See  <a class="medical medical_review" href="/z/d/html/3897.html" rel="external">"Tetanus-diphtheria toxoid vaccination in adults"</a>.)</p><p class="headingAnchor" id="H5"><span class="h3">Diphtheria</span><span class="headingEndMark"> — </span>Diphtheria is common in resource-limited settings. Vaccination is appropriate for travelers to regions where diphtheria is endemic who were vaccinated more than 10 years previously or whose titers are below &gt;0.1 international units/mL . In practice, boosters are frequently given without checking titers. Diphtheria antibody levels could be measured ≥4 weeks after vaccination for immunocompromised travelers traveling to endemic areas. (See  <a class="medical medical_review" href="/z/d/html/3897.html" rel="external">"Tetanus-diphtheria toxoid vaccination in adults"</a>.)</p><p class="headingAnchor" id="H6"><span class="h3">Pertussis</span><span class="headingEndMark"> — </span>Booster vaccination for pertussis is warranted for previously vaccinated adults. Acellular Tdap vaccines have been formulated for adults with reduced quantities of the diphtheria and pertussis to reduce side effects (available as Boostrix or ADACEL). Thus far, this vaccine has not been studied in immunocompromised hosts but may be used in the setting of exposure risk. (See  <a class="medical medical_review" href="/z/d/html/8044.html" rel="external">"Pertussis infection in adolescents and adults: Treatment and prevention"</a>.)</p><p class="headingAnchor" id="H7"><span class="h3">Influenza</span><span class="headingEndMark"> — </span>Vaccination against influenza should occur annually in most immunocompromised hosts; exceptions include those who underwent transplantation, treatment for rejection, or other profound immunosuppression in the few months prior to vaccination. Influenza immunity wanes and it is not known whether immunocompromised travelers should be given booster vaccines prior to travel, although it may be reasonable in certain higher risk settings. Given the year-round influenza activity in the tropics, in general, standard practice is to revaccinate with inactivated vaccine prior to travel if it has been more than 12 months since the last influenza vaccine; reducing this to an interval of over six months may be reasonable in immunocompromised hosts. </p><p>The <a class="drug drug_general" data-topicid="9056" href="/z/d/drug information/9056.html" rel="external">live attenuated influenza vaccine</a> is contraindicated in most immunocompromised hosts. The approach to influenza vaccination in immunocompromised hosts is discussed further separately. (See  <a class="medical medical_review" href="/z/d/html/7007.html" rel="external">"Seasonal influenza vaccination in adults"</a>.) </p><p class="headingAnchor" id="H8"><span class="h3">Pneumococcus</span><span class="headingEndMark"> — </span>The pneumococcal vaccine should be given to immunocompromised hosts  (<a class="graphic graphic_table graphicRef86782" href="/z/d/graphic/86782.html" rel="external">table 6</a>) [<a href="#rid56">56</a>]. </p><p>Issues related to pneumococcal vaccination are discussed further separately. (See  <a class="medical medical_review" href="/z/d/html/7021.html" rel="external">"Pneumococcal vaccination in adults"</a>.)</p><p class="headingAnchor" id="H9"><span class="h3">Measles, mumps, and rubella</span><span class="headingEndMark"> — </span>Vaccination against measles, mumps, and rubella (MMR) in the United States is usually performed with a trivalent live virus vaccine (MMR vaccine). Primary and acquired immunodeficiency states are contraindications to MMR vaccination, including patients who are immunosuppressed with HIV, cellular immune deficiencies, hypogammaglobulinemic and dysgammaglobulinemic states, or who are on immunosuppressive therapy, including biologic therapy [<a href="#rid10">10,37,57,58</a>]. Measles inclusion body encephalitis, pneumonitis, and death as a direct consequence of disseminated measles vaccine virus infection have been reported in immunocompromised individuals inadvertently vaccinated with measles-containing vaccine [<a href="#rid59">59</a>].</p><p>MMR vaccine may be administered to patients with asplenia, renal failure, chronic liver disease, and diabetes but not to those with more severe immunosuppression [<a href="#rid10">10</a>]. Prior to travel to endemic areas, serologic evidence of immunity against measles, mumps, and rubella should be evaluated in transplant recipients. <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">Immune globulin</a> should be considered for seronegative immunosuppressed travelers to areas where measles is endemic [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/z/d/html/3893.html" rel="external">"Measles, mumps, and rubella immunization in adults"</a>.)</p><p>Immunocompromised hosts with hypogammaglobulinemia or other medical conditions and who routinely receive <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> do not usually need additional intramuscular gamma globulin protection for measles, as IVIG is likely to provide higher titer protection than other preparations. Clinicians caring for such patients should evaluate the immunoglobulin dose to determine whether dose adjustment is needed for additional protection. Depending on the formulation, dose, and frequency of IVIG administration, an adjustment in dose or frequency may be indicated to optimize protect against measles in some individuals; refer to the Lexicomp drug monograph for additional information. </p><p class="headingAnchor" id="H10"><span class="h3">Hepatitis B</span><span class="headingEndMark"> — </span>Immunization against hepatitis B is appropriate for certain immunocompromised hosts including hematopoietic cell transplant (HCT) recipients (given their exposure to blood products), diabetics, those who will have new sexual partners while traveling, those living in endemic areas for extended periods, or those who are likely to need transfusions or medical procedures while traveling.</p><p>The efficacy of standard hepatitis B vaccination is reduced when the vaccine is administered following transplantation [<a href="#rid37">37,57,60</a>]. Response rates appear to be adversely affected by age ≥18 years and history of prior chronic graft-versus-host disease but not by donor type, T-cell depletion, adoptive immunotherapy, or <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> [<a href="#rid16">16</a>].</p><p>The serologic response rate can sometimes be improved by administering extra doses of vaccine. Some favor the following regimen for immunocompromised hosts: immunization with a vaccine containing 40 mcg of hepatitis B surface antigen (ie, two 1 mL Engerix-B vaccines, each containing 20 mcg, or a special formulation of Recombivax-HB) at one site, in a three- or four-dose schedule [<a href="#rid10">10,61</a>]. A single higher dose vaccine may provide some protection for those who are nonimmune and vaccinated close to the time of departure (with a plan for follow-up vaccination after travel). Intradermal vaccination may be considered for nonresponders [<a href="#rid62">62</a>]. </p><p class="headingAnchor" id="H11"><span class="h3">Varicella</span><span class="headingEndMark"> — </span>Serologic evidence of immunity against varicella should be evaluated in transplant recipients prior to travel to endemic areas. In general, the attenuated live Oka strain vaccine formulations for varicella should not be used in immunocompromised hosts until there are more data regarding their safety. The <a class="drug drug_general" data-topicid="10038" href="/z/d/drug information/10038.html" rel="external">varicella vaccine</a> may be administered to individuals with asplenia, renal failure, chronic liver disease, diabetes, and some on low-dose immunosuppression, but not to those with more severe immunosuppression [<a href="#rid10">10</a>]. Similarly, zoster vaccine should be avoided in more immunocompromised hosts [<a href="#rid63">63</a>]. (See  <a class="medical medical_review" href="/z/d/html/3893.html" rel="external">"Measles, mumps, and rubella immunization in adults"</a>.) </p><p><a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">Immune globulin</a> or antiviral prophylaxis should be considered for seronegative, severely immunosuppressed travelers to areas where varicella is endemic [<a href="#rid10">10</a>]. Immunocompromised hosts with hypogammaglobulinemia who receive routine IVIG do not need additional antibody protection for varicella, measles, or hepatitis A.</p><p class="headingAnchor" id="H3800781397"><span class="h2">Close contacts and live vaccines</span><span class="headingEndMark"> — </span>Healthy individuals who undergo vaccination with live attenuated vaccine strains can transmit infection to immunocompromised hosts. In general, use of certain live virus vaccines (including oral polio, live attenuated [nasal] influenza, and <a class="drug drug_general" data-topicid="10175" href="/z/d/drug information/10175.html" rel="external">smallpox vaccine</a>) should be deferred in close contacts of immunocompromised hosts [<a href="#rid10">10</a>]. Other live vaccines such as measles, mumps, rubella, yellow fever, oral <em>Salmonella</em>, varicella (Varivax), and zoster (Zostavax) vaccines are much less likely to be transmitted and may be given to close contacts of immunocompromised hosts [<a href="#rid64">64</a>].</p><p class="headingAnchor" id="H21"><span class="h1">ANTIMICROBIAL PROPHYLAXIS</span><span class="headingEndMark"> — </span>When prescribing medications for prevention of travelers' diarrhea and malaria, drug interactions and potential for additive toxicities should be considered  (<a class="graphic graphic_table graphicRef61057" href="/z/d/graphic/61057.html" rel="external">table 7</a>). </p><p>Calcineurin inhibitors and mTOR inhibitors have significant interactions with coadministered drugs that alter CYP3A4 and/or P-gp function. These interactions are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7995.html" rel="external">"Pharmacology of cyclosporine and tacrolimus"</a> and  <a class="medical medical_review" href="/z/d/html/7329.html" rel="external">"Pharmacology of mammalian (mechanistic) target of rapamycin (mTOR) inhibitors"</a>.)</p><p>Use of a drug interaction database, such as the <a class="external" href="/drug-interactions">drug interactions program</a>, is advised. If there are any concerns about the safety of adding a medication, the patient's transplant center team should be consulted. </p><p class="headingAnchor" id="H22"><span class="h2">Travelers' diarrhea</span><span class="headingEndMark"> — </span>Diarrhea affects 10 to 60 percent of travelers to developing regions. Travelers' diarrhea may be life threatening for immunocompromised hosts [<a href="#rid65">65</a>]. Dehydration may compromise renal function and increase toxicity of immunosuppressants such as <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>. Complications of diarrhea may include bacteremia and altered intestinal absorption (with concomitant alterations in the absorption of oral immunosuppressive medications).</p><p>Travelers should be counseled regarding appropriate food and water precautions [<a href="#rid10">10</a>]. In general, travelers should drink boiled or bottled beverages and avoid raw foods (except fruit and vegetables that can be peeled). (See  <a class="medical medical_review" href="/z/d/html/3898.html" rel="external">"Travel advice"</a>.)</p><p>Travelers should carry antimicrobials such as <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">ciprofloxacin</a> or <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> for self-treatment of diarrheal illness lasting more than one to two days  (<a class="graphic graphic_table graphicRef61057" href="/z/d/graphic/61057.html" rel="external">table 7</a>). Potential drug interactions should be considered when starting new antibiotics. Patients with fever, vomiting, and/or bloody stools should consider seeking medical attention. <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">Trimethoprim-sulfamethoxazole</a> is not effective against travelers' diarrhea due to microbial resistance.</p><p>Antimotility agents may delay clearance of toxins from the gut. <a class="drug drug_general" data-topicid="101044" href="/z/d/drug information/101044.html" rel="external">Bismuth subsalicylate</a> (ie, Pepto-Bismol) is converted to salicylic acid and insoluble bismuth salts in the gastrointestinal tract; immunocompromised hosts with decreased renal function may be at higher risk for salicylate toxicity. (See  <a class="medical medical_review" href="/z/d/html/2709.html" rel="external">"Travelers' diarrhea: Epidemiology, microbiology, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/99648.html" rel="external">"Travelers' diarrhea: Treatment and prevention"</a>.)</p><p class="headingAnchor" id="H23"><span class="h2">Malaria</span><span class="headingEndMark"> — </span>Malaria is a significant risk for travelers to endemic areas. Asplenic patients should be aware of their potential increased morbidity and mortality from malaria. There is no evidence that malaria is significantly more common or severe in other immunocompromised hosts apart from HIV-infected individuals; issues related to malaria and HIV infection are discussed in detail separately [<a href="#rid66">66</a>]. (See  <a class="medical medical_review" href="/z/d/html/5722.html" rel="external">"Prevention of malaria infection in travelers"</a>.)</p><p>Immunocompromised hosts should be instructed on ways to minimize insect bites, including use of repellents containing DEET (N,N-diethyl-3-methylbenzamide), bed nets, protective clothing, and permethrin-impregnated clothing [<a href="#rid10">10</a>]. Prophylaxis against malaria should be based on the travel itinerary; this is discussed in detail separately  (<a class="graphic graphic_table graphicRef61057" href="/z/d/graphic/61057.html" rel="external">table 7</a>). (See  <a class="medical medical_review" href="/z/d/html/5722.html" rel="external">"Prevention of malaria infection in travelers"</a>.)</p><p>Drug interactions and QT prolongation may occur in these patients with complex medication regimens; use of a drug interaction calculator is warranted.</p><p class="headingAnchor" id="H3397070304"><span class="h1">PREVENTIVE MEASURES</span></p><p class="headingAnchor" id="H24"><span class="h2">Respiratory infection</span><span class="headingEndMark"> — </span>Endemic fungal pulmonary infections such as histoplasmosis and coccidioidomycosis (in North America) and penicilliosis due to <em>Penicillium marneffei</em> infection (in Southeast Asia) could be acquired during travel [<a href="#rid67">67</a>]. Solid organ transplant (SOT) recipients are at increased risk for invasive fungal infection and should avoid activities such as spelunking and excavating, which have been associated with exposure to <em>Cryptococcus neoformans</em> or endemic fungi. Use of masks may be helpful.</p><p class="headingAnchor" id="H25"><span class="h2">Sun exposure</span><span class="headingEndMark"> — </span>Transplant recipients have a markedly increased risk of skin cancer, which correlates with the intensity of sun exposure. It is important to recommend the use of hats, sunglasses, protective clothing (also useful for arthropod-borne infections), and sun protection lotions with ultraviolet A and B protection.</p><p class="headingAnchor" id="H28"><span class="h1">TRANSPLANT TOURISM</span><span class="headingEndMark"> — </span>Transplant tourism refers to travel for the purpose of receiving or donating a transplanted organ [<a href="#rid68">68</a>]. The number of transplants for United States national waiting list candidates performed in foreign countries has been increasing [<a href="#rid69">69</a>]. Between 2001 and 2006, 373 patients were removed from United States national waiting lists due to transplants performed abroad; 89 percent were kidney transplants. Recipients received foreign transplant in 35 countries, led by China, the Philippines, and India [<a href="#rid69">69</a>]. The majority are "commercial transplants," which include payment to the donor. International transplant organizations have made efforts to decrease purchase and sale of organs on ethical grounds [<a href="#rid70">70</a>].</p><p>The extent and quality of the pretransplant evaluation of the donor and recipient may be variable and the quality of serologic evaluation may be substandard, and prophylactic measures may be incomplete [<a href="#rid46">46</a>]. Foreign-born transplant recipients who return to their country of origin for organ transplants are at risk both for reactivation of latent infections as well as acquisition of new infections [<a href="#rid46">46,71-77</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In a study comparing 540 recipients of commercial renal transplants in India with 75 recipients of living donor renal transplants in the Middle East, the incidence of both HIV infection and hepatitis B virus infection was increased (5 and 8 percent versus 0 and 1 percent, respectively) [<a href="#rid72">72</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among 115 recipients of commercial renal transplants in India, Iraq, and Iran, the posttransplant course was complicated by malaria (10 cases), invasive fungal infections (5 cases), tuberculosis (5 cases), and pneumonia due to various opportunistic pathogens [<a href="#rid74">74</a>]</p><p></p><p>When commercial transplant recipients return to transplant centers in industrialized countries, it is prudent to screen for blood-borne pathogens (including HIV, hepatitis B virus, and hepatitis C virus), as well as bacteremia, urinary tract infection, and other endemic pathogens depending on their clinical course (malaria, tuberculosis, Chagas disease, etc). Optimizing their posttransplant prophylaxis against infection and obtaining further information about their surgical procedure(s) and immunosuppression may also help optimize their care.</p><p class="headingAnchor" id="H852608682"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/115404.html" rel="external">"Society guideline links: Travel medicine"</a>.)</p><p class="headingAnchor" id="H29"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>Immunocompromised hosts are vulnerable to infection and may have a diminished immunologic response to vaccination. Such patients planning to travel overseas should be evaluated by a travel medicine specialist familiar with the patient's immunocompromised state and medications. (See <a class="local">'Introduction'</a> above and <a class="local">'Purpose of pretravel visit'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Travel advice encounters provide the opportunity to review routine immunizations that may have been overlooked. These include tetanus, diphtheria, pertussis, influenza, pneumococcus, measles, mumps, rubella, hepatitis B, and varicella. (See <a class="local">'Routine vaccines'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Appropriate travel vaccines depend on the individual itinerary but may include typhoid, polio, meningococcus, rabies, and Japanese encephalitis. (See <a class="local">'Travel vaccines'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The following live vaccines are generally contraindicated in immunocompromised hosts: measles, mumps, rubella, varicella, yellow fever, and Bacille Calmette-Guérin. Immunoglobulin may provide protection against measles, mumps, rubella, varicella, hepatitis A, and rabies when vaccination is contraindicated or there is insufficient time to develop immunity. (See <a class="local">'Routine vaccines'</a> above and <a class="local">'Travel vaccines'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prophylactic and preventive measures are warranted for illnesses that cannot be prevented by vaccination. These include travelers' diarrhea, malaria and other arthropod-borne illnesses, respiratory infection, sun exposure, and altitude. (See <a class="local">'Antimicrobial prophylaxis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Transplant tourism (travel for the purpose of receiving or donating a transplanted organ) is increasing. When commercial transplant recipients return to transplant centers in industrialized countries, it is prudent to screen for blood-borne pathogens (including HIV, hepatitis B virus, and hepatitis C virus), as well as bacteremia, urinary tract infection, and other endemic pathogens depending on their clinical course (malaria, tuberculosis, Chagas disease, etc). (See <a class="local">'Transplant tourism'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Buchan CA, Kotton CN, AST Infectious Diseases Community of Practice. Travel medicine, transplant tourism, and the solid organ transplant recipient-Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant 2019; 33:e13529.</a></li><li><a class="nounderline abstract_t">Clemente WT, Pierrotti LC, Abdala E, et al. Recommendations for Management of Endemic Diseases and Travel Medicine in Solid-Organ Transplant Recipients and Donors: Latin America. Transplantation 2018; 102:193.</a></li><li><a class="nounderline abstract_t">Chen LH, Connor BA. Is standby therapy for Covid-19 a practical option for travellers? J Travel Med 2022; 29.</a></li><li><a class="nounderline abstract_t">Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014; 58:e44.</a></li><li><a class="nounderline abstract_t">Boggild AK, Sano M, Humar A, et al. Travel patterns and risk behavior in solid organ transplant recipients. J Travel Med 2004; 11:37.</a></li><li><a class="nounderline abstract_t">Roukens AH, van Dissel JT, de Fijter JW, Visser LG. Health preparations and travel-related morbidity of kidney transplant recipients traveling to developing countries. Clin Transplant 2007; 21:567.</a></li><li><a class="nounderline abstract_t">Committee to Advise on Tropical Medicine and Travel (CATMAT). The immunocompromised traveller. An Advisory Committee Statement (ACS). Can Commun Dis Rep 2007; 33:1.</a></li><li><a class="nounderline abstract_t">Schwartz BS, Rosen J, Han PV, et al. Immunocompromised Travelers: Demographic Characteristics, Travel Destinations, and Pretravel Health Care from the U.S. Global TravEpiNet Consortium. Am J Trop Med Hyg 2015; 93:1110.</a></li><li><a class="nounderline abstract_t">Dekkiche S, de Vallière S, D'Acremont V, Genton B. Travel-related health risks in moderately and severely immunocompromised patients: a case-control study. J Travel Med 2016; 23.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Approach to the immunocompromised traveler. https://wwwnc.cdc.gov/travel/yellowbook/2020/travelers-with-additional-considerations/immunocompromised-travelers (Accessed on January 19, 2021).</li><li><a class="nounderline abstract_t">Madsalae K, Ngamprasertchai T, Lawpoolsri S, et al. Adherence and Health Problems in Thai Travellers Living with HIV. Trop Med Infect Dis 2022; 7.</a></li><li><a class="nounderline abstract_t">Elkayam O, Caspi D, Reitblatt T, et al. The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum 2004; 33:283.</a></li><li><a class="nounderline abstract_t">van der Velden AM, Claessen AM, van Velzen-Blad H, et al. Vaccination responses and lymphocyte subsets after autologous stem cell transplantation. Vaccine 2007; 25:8512.</a></li><li><a class="nounderline abstract_t">Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007; 357:2601.</a></li><li><a class="nounderline abstract_t">Kotton CN. Immunization after kidney transplantation-what is necessary and what is safe? Nat Rev Nephrol 2014; 10:555.</a></li><li><a class="nounderline abstract_t">Jaffe D, Papadopoulos EB, Young JW, et al. Immunogenicity of recombinant hepatitis B vaccine (rHBV) in recipients of unrelated or related allogeneic hematopoietic cell (HC) transplants. Blood 2006; 108:2470.</a></li><li><a class="nounderline abstract_t">Ryan ET, Kain KC. Health advice and immunizations for travelers. N Engl J Med 2000; 342:1716.</a></li><li><a class="nounderline abstract_t">Günther M, Stark K, Neuhaus R, et al. Rapid decline of antibodies after hepatitis A immunization in liver and renal transplant recipients. Transplantation 2001; 71:477.</a></li><li><a class="nounderline abstract_t">Rendi-Wagner P, Korinek M, Winkler B, et al. Persistence of seroprotection 10 years after primary hepatitis A vaccination in an unselected study population. Vaccine 2007; 25:927.</a></li><li><a class="nounderline abstract_t">Arslan M, Wiesner RH, Poterucha JJ, Zein NN. Safety and efficacy of hepatitis A vaccination in liver transplantation recipients. Transplantation 2001; 72:272.</a></li><li><a class="nounderline abstract_t">Dumot JA, Barnes DS, Younossi Z, et al. Immunogenicity of hepatitis A vaccine in decompensated liver disease. Am J Gastroenterol 1999; 94:1601.</a></li><li><a class="nounderline abstract_t">Stark K, Günther M, Neuhaus R, et al. Immunogenicity and safety of hepatitis A vaccine in liver and renal transplant recipients. J Infect Dis 1999; 180:2014.</a></li><li><a class="nounderline abstract_t">Askling HH, Rombo L, van Vollenhoven R, et al. Hepatitis A vaccine for immunosuppressed patients with rheumatoid arthritis: a prospective, open-label, multi-centre study. Travel Med Infect Dis 2014; 12:134.</a></li><li><a class="nounderline abstract_t">Garcia Garrido HM, Wieten RW, Grobusch MP, Goorhuis A. Response to Hepatitis A Vaccination in Immunocompromised Travelers. J Infect Dis 2015; 212:378.</a></li><li><a class="nounderline abstract_t">Rosdahl A, Herzog C, Frösner G, et al. An extra priming dose of hepatitis A vaccine to adult patients with rheumatoid arthritis and drug induced immunosuppression - A prospective, open-label, multi-center study. Travel Med Infect Dis 2018; 21:43.</a></li><li><a class="nounderline abstract_t">Nelson NP. Updated Dosing Instructions for Immune Globulin (Human) GamaSTAN S/D for Hepatitis A Virus Prophylaxis. MMWR Morb Mortal Wkly Rep 2017; 66:959.</a></li><li class="breakAll">World Health Organization. Immunization, Vaccines and Biologicals: Research and Development. http://www.who.int/vaccine_research/diseases/diarrhoeal/en/index7.html (Accessed on February 04, 2015).</li><li class="breakAll">United States Centers for Disease Control and Prevention. Typhoid Fever and Paratyphoid Fever. https://www.cdc.gov/typhoid-fever/health-professional.html (Accessed on January 19, 2021).</li><li><a class="nounderline abstract_t">Begier EM, Burwen DR, Haber P, et al. Postmarketing safety surveillance for typhoid fever vaccines from the Vaccine Adverse Event Reporting System, July 1990 through June 2002. Clin Infect Dis 2004; 38:771.</a></li><li><a class="nounderline abstract_t">Ljungman P, Aschan J, Gustafsson B, et al. Long-term immunity to poliovirus after vaccination of allogeneic stem cell transplant recipients. Bone Marrow Transplant 2004; 34:1067.</a></li><li class="breakAll">Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020 https://www.cdc.gov/mmwr/volumes/69/rr/rr6909a1.htm?s_cid=rr6909a1_w (Accessed on September 24, 2020).</li><li><a class="nounderline abstract_t">Parkkali T, Käyhty H, Lehtonen H, et al. Tetravalent meningococcal polysaccharide vaccine is immunogenic in adult allogeneic BMT recipients. Bone Marrow Transplant 2001; 27:79.</a></li><li><a class="nounderline abstract_t">Cheng MP, Pandit A, Antin JH, et al. Safety and immunogenicity of conjugate quadrivalent meningococcal vaccination after hematopoietic cell transplantation. Blood Adv 2018; 2:1272.</a></li><li><a class="nounderline abstract_t">Patel SR, Ortín M, Cohen BJ, et al. Revaccination with measles, tetanus, poliovirus, Haemophilus influenzae type B, meningococcus C, and pneumococcus vaccines in children after hematopoietic stem cell transplantation. Clin Infect Dis 2007; 44:625.</a></li><li><a class="nounderline abstract_t">Yu JW, Borkowski A, Danzig L, et al. Immune response to conjugated meningococcal C vaccine in pediatric oncology patients. Pediatr Blood Cancer 2007; 49:918.</a></li><li><a class="nounderline abstract_t">Nelson DR, Fadrowski J, Neu A. Immunogenicity of the meningococcal polysaccharide conjugate vaccine in pediatric kidney transplant patients. Pediatr Nephrol 2018; 33:1037.</a></li><li><a class="nounderline abstract_t">Duchini A, Goss JA, Karpen S, Pockros PJ. Vaccinations for adult solid-organ transplant recipients: current recommendations and protocols. Clin Microbiol Rev 2003; 16:357.</a></li><li><a class="nounderline abstract_t">Cetron MS, Marfin AA, Julian KG, et al. Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002. MMWR Recomm Rep 2002; 51:1.</a></li><li><a class="nounderline abstract_t">Fishman JA. Smallpox and live-virus vaccination in transplant recipients. Am J Transplant 2003; 3:786.</a></li><li class="breakAll">Ljungman P. Vaccination of Transplant Recipients. In: Transplant Infections, Bowden RA, Ljungman P, Paya CV (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2003. p.611.</li><li class="breakAll">Mileno M. Preparation of Immunocompromised Travelers. In: Travel Medicine, 1st ed, Keystone JS, Freedman DP, Nothdurft HD, Connor BA (Eds), Mosby, Edinburgh 2004. p.249.</li><li><a class="nounderline abstract_t">Miranda LJC, Agena F, Sartori AMC, et al. Awareness of Inadvertent Use of Yellow Fever Vaccine Among Recipients of Renal Transplant. Transplant Proc 2020; 52:1291.</a></li><li><a class="nounderline abstract_t">Bühler S, Eperon G, Ribi C, et al. Vaccination recommendations for adult patients with autoimmune inflammatory rheumatic diseases. Swiss Med Wkly 2015; 145:w14159.</a></li><li><a class="nounderline abstract_t">Domingo C, Niedrig M. Safety of 17D derived yellow fever vaccines. Expert Opin Drug Saf 2009; 8:211.</a></li><li><a class="nounderline abstract_t">Kengsakul K, Sathirapongsasuti K, Punyagupta S. Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection. J Med Assoc Thai 2002; 85:131.</a></li><li><a class="nounderline abstract_t">Kennedy SE, Shen Y, Charlesworth JA, et al. Outcome of overseas commercial kidney transplantation: an Australian perspective. Med J Aust 2005; 182:224.</a></li><li><a class="nounderline abstract_t">Burkhard J, Ciurea A, Gabay C, et al. Long-term immunogenicity after yellow fever vaccination in immunosuppressed and healthy individuals. Vaccine 2020; 38:3610.</a></li><li><a class="nounderline abstract_t">Wyplosz B, Burdet C, François H, et al. Persistence of yellow fever vaccine-induced antibodies after solid organ transplantation. Am J Transplant 2013; 13:2458.</a></li><li><a class="nounderline abstract_t">Gowda R, Cartwright K, Bremner JA, Green ST. Yellow fever vaccine: a successful vaccination of an immunocompromised patient. Eur J Haematol 2004; 72:299.</a></li><li><a class="nounderline abstract_t">Receveur MC, Thiébaut R, Vedy S, et al. Yellow fever vaccination of human immunodeficiency virus-infected patients: report of 2 cases. Clin Infect Dis 2000; 31:E7.</a></li><li><a class="nounderline abstract_t">Tattevin P, Depatureaux AG, Chapplain JM, et al. Yellow fever vaccine is safe and effective in HIV-infected patients. AIDS 2004; 18:825.</a></li><li><a class="nounderline abstract_t">Ho YL, Enohata T, Lopes MH, De Sousa Dos Santos S. Vaccination in Brazilian HIV-infected adults: a cross-sectional study. AIDS Patient Care STDS 2008; 22:65.</a></li><li><a class="nounderline abstract_t">Mota LM, Oliveira AC, Lima RA, et al. [Vaccination against yellow fever among patients on immunosuppressors with diagnoses of rheumatic diseases]. Rev Soc Bras Med Trop 2009; 42:23.</a></li><li><a class="nounderline abstract_t">Gibbons RV, Rupprecht CE. Postexposure rabies prophylaxis in immunosuppressed patients. JAMA 2001; 285:1574.</a></li><li><a class="nounderline abstract_t">Inactivated Japanese encephalitis virus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1993; 42:1.</a></li><li><a class="nounderline abstract_t">Danziger-Isakov L, Kumar D, AST Infectious Diseases Community of Practice. Vaccination in solid organ transplantation. Am J Transplant 2013; 13 Suppl 4:311.</a></li><li><a class="nounderline abstract_t">Avery RK, Ljungman P. Prophylactic measures in the solid-organ recipient before transplantation. Clin Infect Dis 2001; 33 Suppl 1:S15.</a></li><li><a class="nounderline abstract_t">Molrine DC, Hibberd PL. Vaccines for transplant recipients. Infect Dis Clin North Am 2001; 15:273.</a></li><li class="breakAll">Merck. M-M-R® II (Measles, Mumps, and Rubella Virus Vaccine Live). http://www.merck.com/product/usa/pi_circulars/m/mmr_ii/mmr_ii_pi.pdf (Accessed on February 02, 2021).</li><li><a class="nounderline abstract_t">Hayney MS, Welter DL, Reynolds AM, et al. High-dose hepatitis B vaccine in patients waiting for lung transplantation. Pharmacotherapy 2003; 23:555.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Recommended Adult Immunization Schedule, United States - 2016. http://www.cdc.gov/vaccines/schedules/downloads/adult/adult-combined-schedule.pdf (Accessed on October 06, 2016).</li><li><a class="nounderline abstract_t">Filippelli M, Lionetti E, Gennaro A, et al. Hepatitis B vaccine by intradermal route in non responder patients: an update. World J Gastroenterol 2014; 20:10383.</a></li><li><a class="nounderline abstract_t">Harpaz R, Ortega-Sanchez IR, Seward JF, Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008; 57:1.</a></li><li><a class="nounderline abstract_t">Marin M, Güris D, Chaves SS, et al. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56:1.</a></li><li><a class="nounderline abstract_t">Beeching NJ, Carratalà J, Razonable RR, et al. Traveler's Diarrhea Recommendations for Solid Organ Transplant Recipients and Donors. Transplantation 2018; 102:S35.</a></li><li class="breakAll">Conlon CP. The Immunocompromised Traveler. In: Textbook of Travel Medicine and Health, 2nd ed, DuPont HL, Steffer R (Eds), BC Decker, 2001. p.464.</li><li><a class="nounderline abstract_t">Panackal AA, Hajjeh RA, Cetron MS, Warnock DW. Fungal infections among returning travelers. Clin Infect Dis 2002; 35:1088.</a></li><li><a class="nounderline abstract_t">Evans RW. Ethnocentrism is an unacceptable rationale for health care policy: a critique of transplant tourism position statements. Am J Transplant 2008; 8:1089.</a></li><li><a class="nounderline abstract_t">Merion RM, Barnes AD, Lin M, et al. Transplants in Foreign Countries Among Patients Removed from the US Transplant Waiting List. Am J Transplant 2008; 8:988.</a></li><li><a class="nounderline abstract_t">Participants in the International Summit on Transplant Tourism and Organ Trafficking Convened by the Transplantation Society and International Society of Nephrology in Istanbul, Turkey, April 30-May 2, 2008. The Declaration of Istanbul on organ trafficking and transplant tourism. Transplantation 2008; 86:1013.</a></li><li><a class="nounderline abstract_t">Martín-Dávila P, Fortún J, López-Vélez R, et al. Transmission of tropical and geographically restricted infections during solid-organ transplantation. Clin Microbiol Rev 2008; 21:60.</a></li><li><a class="nounderline abstract_t">Commercially motivated renal transplantation: results in 540 patients transplanted in India. The Living Non-Related Renal Transplant Study Group. Clin Transplant 1997; 11:536.</a></li><li><a class="nounderline abstract_t">Harling R, Turbitt D, Millar M, et al. Passage from India: an outbreak of hepatitis B linked to a patient who acquired infection from health care overseas. Public Health 2007; 121:734.</a></li><li><a class="nounderline abstract_t">Sever MS, Kazancioğlu R, Yildiz A, et al. Outcome of living unrelated (commercial) renal transplantation. Kidney Int 2001; 60:1477.</a></li><li><a class="nounderline abstract_t">Canales MT, Kasiske BL, Rosenberg ME. Transplant tourism: Outcomes of United States residents who undergo kidney transplantation overseas. Transplantation 2006; 82:1658.</a></li><li><a class="nounderline abstract_t">Geddes CC, Henderson A, Mackenzie P, Rodger SC. Outcome of patients from the west of Scotland traveling to Pakistan for living donor kidney transplants. Transplantation 2008; 86:1143.</a></li><li><a class="nounderline abstract_t">Gill J, Madhira BR, Gjertson D, et al. Transplant tourism in the United States: a single-center experience. Clin J Am Soc Nephrol 2008; 3:1820.</a></li></ol></div><div id="topicVersionRevision">Topic 3896 Version 30.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30859623" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Travel medicine, transplant tourism, and the solid organ transplant recipient-Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29381647" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Recommendations for Management of Endemic Diseases and Travel Medicine in Solid-Organ Transplant Recipients and Donors: Latin America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36263880" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Is standby therapy for Covid-19 a practical option for travellers?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24311479" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14769286" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Travel patterns and risk behavior in solid organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17645721" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Health preparations and travel-related morbidity of kidney transplant recipients traveling to developing countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17520776" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The immunocompromised traveller. An Advisory Committee Statement (ACS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26304922" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Immunocompromised Travelers: Demographic Characteristics, Travel Destinations, and Pretravel Health Care from the U.S. Global TravEpiNet Consortium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26929155" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Travel-related health risks in moderately and severely immunocompromised patients: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26929155" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Travel-related health risks in moderately and severely immunocompromised patients: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35878140" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Adherence and Health Problems in Thai Travellers Living with HIV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14978666" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17996989" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Vaccination responses and lymphocyte subsets after autologous stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18094380" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Infection in solid-organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25072119" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Immunization after kidney transplantation-what is necessary and what is safe?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16763208" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Immunogenicity of recombinant hepatitis B vaccine (rHBV) in recipients of unrelated or related allogeneic hematopoietic cell (HC) transplants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10841875" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Health advice and immunizations for travelers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11233913" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Rapid decline of antibodies after hepatitis A immunization in liver and renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17005304" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Persistence of seroprotection 10 years after primary hepatitis A vaccination in an unselected study population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11477352" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Safety and efficacy of hepatitis A vaccination in liver transplantation recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10364031" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Immunogenicity of hepatitis A vaccine in decompensated liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10558960" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Immunogenicity and safety of hepatitis A vaccine in liver and renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24529746" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Hepatitis A vaccine for immunosuppressed patients with rheumatoid arthritis: a prospective, open-label, multi-centre study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25649170" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Response to Hepatitis A Vaccination in Immunocompromised Travelers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29229311" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : An extra priming dose of hepatitis A vaccine to adult patients with rheumatoid arthritis and drug induced immunosuppression - A prospective, open-label, multi-center study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28910270" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Updated Dosing Instructions for Immune Globulin (Human) GamaSTAN S/D for Hepatitis A Virus Prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28910270" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Updated Dosing Instructions for Immune Globulin (Human) GamaSTAN S/D for Hepatitis A Virus Prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28910270" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Updated Dosing Instructions for Immune Globulin (Human) GamaSTAN S/D for Hepatitis A Virus Prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14999618" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Postmarketing safety surveillance for typhoid fever vaccines from the Vaccine Adverse Event Reporting System, July 1990 through June 2002.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15489876" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Long-term immunity to poliovirus after vaccination of allogeneic stem cell transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15489876" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Long-term immunity to poliovirus after vaccination of allogeneic stem cell transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11244441" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Tetravalent meningococcal polysaccharide vaccine is immunogenic in adult allogeneic BMT recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29871892" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Safety and immunogenicity of conjugate quadrivalent meningococcal vaccination after hematopoietic cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17278051" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Revaccination with measles, tetanus, poliovirus, Haemophilus influenzae type B, meningococcus C, and pneumococcus vaccines in children after hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17366523" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Immune response to conjugated meningococcal C vaccine in pediatric oncology patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29557497" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Immunogenicity of the meningococcal polysaccharide conjugate vaccine in pediatric kidney transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12857772" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Vaccinations for adult solid-organ transplant recipients: current recommendations and protocols.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12437192" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12814470" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Smallpox and live-virus vaccination in transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12814470" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Smallpox and live-virus vaccination in transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12814470" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Smallpox and live-virus vaccination in transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32505502" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Awareness of Inadvertent Use of Yellow Fever Vaccine Among Recipients of Renal Transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26218860" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Vaccination recommendations for adult patients with autoimmune inflammatory rheumatic diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19309249" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Safety of 17D derived yellow fever vaccines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12075714" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15748132" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Outcome of overseas commercial kidney transplantation: an Australian perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31911033" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Long-term immunogenicity after yellow fever vaccination in immunosuppressed and healthy individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23834702" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Persistence of yellow fever vaccine-induced antibodies after solid organ transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15089771" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Yellow fever vaccine: a successful vaccination of an immunocompromised patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11017859" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Yellow fever vaccination of human immunodeficiency virus-infected patients: report of 2 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15075524" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Yellow fever vaccine is safe and effective in HIV-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18095834" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Vaccination in Brazilian HIV-infected adults: a cross-sectional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19287931" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : [Vaccination against yellow fever among patients on immunosuppressors with diagnoses of rheumatic diseases].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11268256" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Postexposure rabies prophylaxis in immunosuppressed patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8381504" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Inactivated Japanese encephalitis virus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23465023" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Vaccination in solid organ transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11389517" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Prophylactic measures in the solid-organ recipient before transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11301820" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Vaccines for transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11301820" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Vaccines for transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12741428" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : High-dose hepatitis B vaccine in patients waiting for lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12741428" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : High-dose hepatitis B vaccine in patients waiting for lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25132754" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Hepatitis B vaccine by intradermal route in non responder patients: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18528318" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17585291" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29381576" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Traveler's Diarrhea Recommendations for Solid Organ Transplant Recipients and Donors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29381576" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Traveler's Diarrhea Recommendations for Solid Organ Transplant Recipients and Donors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12384843" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Fungal infections among returning travelers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18444938" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Ethnocentrism is an unacceptable rationale for health care policy: a critique of transplant tourism position statements.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18336701" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Transplants in Foreign Countries Among Patients Removed from the US Transplant Waiting List.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18946336" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : The Declaration of Istanbul on organ trafficking and transplant tourism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18202437" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Transmission of tropical and geographically restricted infections during solid-organ transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9408681" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Commercially motivated renal transplantation: results in 540 patients transplanted in India. The Living Non-Related Renal Transplant Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17573083" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Passage from India: an outbreak of hepatitis B linked to a patient who acquired infection from health care overseas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11576362" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Outcome of living unrelated (commercial) renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17198255" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Transplant tourism: Outcomes of United States residents who undergo kidney transplantation overseas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18946355" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Outcome of patients from the west of Scotland traveling to Pakistan for living donor kidney transplants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18922987" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Transplant tourism in the United States: a single-center experience.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
